National medicines policies – a review of the evolution and development processes by Joëlle M Hoebert et al.
Hoebert et al. Journal of Pharmaceutical Policy and Practice 2013, 6:5
http://www.joppp.org/content/6/1/5REVIEW Open AccessNational medicines policies – a review of the
evolution and development processes
Joëlle M Hoebert1, Liset van Dijk2, Aukje K Mantel-Teeuwisse1*, Hubert GM Leufkens1 and Richard O Laing3Abstract
Objectives: Continuous provision of appropriate medicines of assured quality, in adequate quantities, and at
reasonable prices is a concern for all national governments. A national medicines policy (NMP) developed in a
collaborative fashion identifies strategies needed to meet these objectives and provides a comprehensive
framework to develop all components of a national pharmaceutical sector. To meet the health needs of the
population, there is a general need for medicine policies based on universal principles, but nevertheless adapted to
the national situation. This review aims to provide a quantitative and qualitative (describing the historical
development) study of the development process and evolution of NMPs.
Methods: The number of NMPs and their current status has been obtained from the results of the assessment of
WHO Level I indicators. The policy formulation process is examined in more detail with case studies from four
countries: Sri Lanka, Australia, former Yugoslav Republic of Macedonia and South Africa.
Results: The number of NMPs worldwide has increased in the last 25 years with the highest proportional increase
in the last 5–10 years in high-income countries. Higher income countries seem to have more NMP implementation
plans available and have updated their NMP more recently. The four case studies show that the development of a
NMP is a complex process that is country specific. In addition, it demonstrates that an appropriate political window
is needed for the policy to be passed (for South Africa and the FYR Macedonia, a major political event acted as a
trigger for initiating the policy development). Policy-making does not stop with the official adoption of a policy but
should create mechanisms for implementation and monitoring. The NMPs of the FYR Macedonia and Australia
provide indicators for monitoring.
Conclusions: To date, not all countries have a NMP since political pressure by national experts or non-governmental
organizations is generally needed to establish a NMP. Case studies in four countries showed that the policy process is
just as important as the policy document since the process must create a mechanism by which all stakeholders are
brought together and a sense of collective ownership of the final policy may be achieved.
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Medicines play a major role in protecting, maintaining
and restoring people’s health. The regular provision of
appropriate medicines of assured quality, in adequate
quantities and at reasonable prices, is therefore a concern
for all national governments [1,2]. While overuse and
misuse of medicines are common in many countries, the
poor availability of essential medicines is a major problem
in low- and middle-income countries (LMIC) and for the* Correspondence: a.k.mantel@uu.nl
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reproduction in any medium, provided the orpoorer segments of the population [3]. In contrast to
wealthier countries, up to 90% of the populations in
developing countries purchase medicines with out-of-
pocket payments [4,5]. Several factors contribute to
increased spending on medicines across all income
levels: the emergence of new diseases, population age-
ing, increasing antimicrobial resistance, increasing use
of preventive medicines, and the availability of new and
expensive medicines displaying little or no therapeutic
benefit over existing treatments [6,7]. In addition to
high expenditures, factors such as changing patterns of
morbidity, the increasing role of the private sector inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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presence or absence of health insurance schemes, and
the effect of globalization and trade agreements also
have their impact on access [8,9]. The existence of (a
combination of ) these factors is country specific and
relates to the national political situation, as well as the
economical situation and existing legislation.
These access problems have persisted despite efforts
by governments, development agencies and the World
Health Organization (WHO) to improve access to essen-
tial medicines, to promote rational use and to ensure that
quality assured medicines are used. The reasons for the
failure to achieve universal access and rational use are
complex, may differ among countries, and involve a wide
range of stakeholders. Thus, there is a general need for
medicine policies based on universal principles, but never-
theless adapted to the national situation of a country, to
meet the health needs of the inhabitants [10]. A national
medicines policy (NMP) helps to identify strategies to
meet these objectives, as it provides a comprehensive
framework for the development of all components of the
national pharmaceutical sector. A NMP typically has a
future perspective of 10 years to adapt to the changing
environment, and should be combined with monitoring
and periodic reviews [10].
The final content of a NMP will vary among countries,
as it depends on cultural and historical factors, including
a country’s institutional capacity to regulate and enforce
quality assurance, the political values of the government,
the level of spending on pharmaceuticals, and economic
development. As these factors develop continuously over
time it is important to regularly update any NMP. Further-
more, the NMP must take into consideration that the
elements are inter-linked and that a holistic approach is
required; therefore, the development process must be
clearly defined. The policy then becomes an expression of
the government’s commitment to provide medicines to
the population and is a framework for action [11].
Since the first publication of WHO’s ‘Guidelines for
Developing National Drug Policies’ in 1988, many coun-
tries have tried to improve people’s access to essential
medicines by formulating a NMP [12]. The present article
reviews the historical development of NMPs in general, e.g.
in terms of numbers and the status of implementation
across various income levels. In addition, the policy formu-
lation process is examined in more detail with case studies
from four countries describing the historical development
in these countries.
Methods
This review is a quantitative and qualitative (describing
the historical development) study of the evolution and
development process of NMPs. The number of NMPs
and their current status have been obtained from theresults of the WHO level 1 survey 1999 (as appeared in
the World Medicines Situation Report 2004), the assess-
ment of WHO Level I indicators conducted in 2007 and
the global overview of pharmaceutical sector country
profiles in 2011 [13,14]. Level I indicators measure the
existence and performance of key national pharmaceut-
ical structures and processes within countries.
In the qualitative part of this study, four examples of
national medicines policy formulation processes are
presented: Sri Lanka (small country with a long history
of pharmaceutical policy innovation), Australia (high-in-
come Western country with an integrated policy), South
Africa (large country, political struggle needed for a radical
change) and the former Yugoslav Republic of Macedonia
(small country with a limited capacity and affected by civil
disturbance in neighboring countries). These countries
were chosen because they reflect diversity in the devel-
opment process of the NMP and represent a range of
economic statuses. Information about these historical
processes was obtained using PubMed, the 2004 World
Medicines Situation report and other literature sources
(year of data collection: 2009). Three experts, closely
involved in the policy formulation processes in three of
the four countries, were asked by email to validate the
descriptions of the policy processes (July/August 2009).
Results
Historical development of national medicines policies
Role of WHO
In 1985, the Nairobi conference on ‘The Rational Use of
Drugs’ took place [15]. The experts at this conference
aimed to ensure access to essential medicines and rational
use of medicines for all people, especially in developing
countries. This meeting resulted in the recommendation
that a NMP should be defined in each country to ensure
that essential medicines of assured quality, safety and effi-
cacy would be available at affordable prices to all people
who need them at the right moment and at the right place
and would be used appropriately. Primary responsibility
for overseeing rational medicine use would rest with the
individual member governments assisted by WHO. It was
felt that WHO should disseminate guidelines on NMPs at
the international level and this was eventually done in
1988 [1,12]. In 1989, 14 countries across the world had
formulated or updated a NMP within the previous 10
years [16]. Since then, many countries have formulated a
NMP.
Trends over time
Increased awareness of the importance of a NMP in
countries with limited resources is reflected by their early
development in these countries. From 1985 onwards, the
number of NMPs established in low-income countries
increased rapidly, with the largest increase between 1985
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began only in 1995. Figure 1 shows trends for the formula-
tion of NMPs between 1999–2011, by income level. It re-
veals that the percentage of NMPs increased across all
income categories but the highest proportional increase
was seen in high-income countries, from 18% in 1999 to
almost 80% in 2011.
Situation 2011
In 2011, WHO surveyed 165 countries and found that
133 (81%) countries had a NMP. A NMP implementa-
tion plan existed in 97 out of 155 (62.6%) responding
countries (see Table 1). Table 1 shows that low-income
countries were more likely to have a NMP compared to
high-income countries. Nevertheless, these developed
countries have updated their NMP more recently com-
pared with low-income countries (data not shown).
Development processes
A NMP is the result of a complex process of develop-
ment, implementation and monitoring. First, the policy
development process results in the formulation of a
NMP. Secondly, strategies and activities that aim to
achieve policy objectives are implemented by various
stakeholders. Finally, the effect of these activities is mon-
itored and the policy is adjusted as necessary. Through-
out the process careful planning, consideration of the
political dynamics and the involvement of all stake-
holders is needed. Other key stakeholders besides the
Ministry of Health can be found among regulators, pro-
fessional organizations, producers, importers and distribu-
tors, health care professionals, patients and consumers,
academics, civil society, health planners and managers,
health finance authorities, insurance organizations, mediaFigure 1 Trends in the formulation of national medicines
policies (NMP), by countries’ level of income, 1999, 2003, 2007
and 2011. Source: WHO level 1 survey (as appeared in the World
Medicines Situation Report 2004), and the global overview of
pharmaceutical sector country profiles (2011). Percentages are based
on number of countries surveyed by WHO.and health/medicines donors, funders and major non-
governmental organizations. It is important to identify
political allies, and to maintain their support throughout
the process [10,17].
The process of developing a NMP is almost exclusively
a national matter and will differ among countries and re-
gions with disparate income levels. In some countries, the
NMP has been introduced as a complete entity (though
not necessarily implemented as such), but in other coun-
tries the NMP is developed in components. In many low-
and middle-income countries, a national essential medi-
cines programme was the motivation for establishing such
a policy and usually emphasized the selection, procure-
ment, distribution and use of pharmaceuticals in the pub-
lic sector [18]. During the last decade, these programmes
have recognised the importance of finance tracking, medi-
cine prices and financial management [19].
In high-income countries, the strategic goals of a
NMP are generally found in various laws, regulations,
and administrative procedures - rarely in a single docu-
ment. The lack of an integrated national policy is unsat-
isfactory from a public health point of view, as some
policies affecting medicines seem to contradict or under-
mine others [17]. Although medicines policies have gen-
erally been developed at a national level in high-income
countries, international harmonization might hamper
the development of a NMP within a country.
In the past two decades, market-oriented health sector
reforms for meeting new health needs and requirements
have been underway or under consideration throughout
the world and at all income levels. Although this trend
may undermine public services and pose a threat to
equity in the well established social-welfare systems of
high-income countries, such developments pose more
immediate threats to the fragile systems in middle-
income and low-income countries [20,21]. The pharma-
ceutical sector and its policies are influenced by health
sector reforms with increased decentralisation, shifting
roles and responsibilities from the central department of
pharmacy management to the district level and the
establishment of district pharmaceutical management
points. A NMP must address the implications of an
overall health system policy; there are clearly pharma-
ceutical policy aspects that must remain centralised such
as regulation, quality assurance and public sector pro-
curement. The process of deciding which functions fall
into which area is complex and difficult and the decision
to proceed, and the subsequent success of implementa-
tion, depend on political support and the capacity at a
local level. Thus, the content of a NMP must be regu-
larly monitored and adjusted if necessary.
Table 2 presents background information on popula-
tion and economic data of the four countries selected
for the case studies. A full description of the NMP
Table 1 Status of national medicines policies (NMP) by income level, 2011 [13]
Country income level
Low (36) Lower-middle (53) Upper-middle (55) High (50) Global Total (194)














Yes 30 96.8 34 87.2 23 79.3 15 83.3 102 87.2
n 31 39 29 18 117
NMP exists Yes 31 93.9 39 86.7 33 68.8 30 76.9 133 80.6
n 33 45 48 39 165
NMP implementation
plan exists
Yes 25 75.8 21 47.7 24 57.1 27 75.0 97 62.6
n 33 44 42 36 155
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in the Appendix; the most important aspects of the de-
velopment processes are outlined below.
Sri Lanka’s national medicines policy process: promoting
generics despite opposition
The two first attempts (in 1991 and 1996) to develop a
NMP failed. Two important factors in these failures were
the absence of participation by civil society and the lack
of a health reform campaign by civil society organiza-
tions. Thereafter, Health Action International Asia –
Pacific and its network partner ‘The Peoples Movement
for Rights of Patients’ began lobbying for a NMP and
convened a number of national seminars, meetings and
workshops on the need for a NMP, which started a
development process including all stakeholders in 2005.
Although accepted by consensus and endorsed by the
government in 2006, the current NMP has not been
implemented due to strong lobbying against the NMP
by the private pharmaceutical industry even though they
had participated as a stakeholder. Generic promotionTable 2 General statistics of Sri Lanka, Australia, South Africa
Sri Lanka Au
Year of policy formulation 2006 19
World Bank income level* Lower-middle Hi
Region South East Asia W
Total population (million inhabitants)** 19.2 20
Gross national income per capita (PPP international $)** 3,730 33
Life expectancy at birth m/f (years)** 69/76 79
Total expenditure on health per capita
(international $, 2006)**
213 3,1
Total expenditure on health as % of GDP (2006)** 4.2 8.7
*Income groups are classified according to World Bank estimates of 2008 Gross Nat
**Figures are for 2006. Source: World Health Statistics 2008.
GDP gross domestic product, PPP Purchasing Power Parity, m/f male/female.and substitution are two components in the NMP that
the industry vehemently opposed and they have success-
fully lobbied to delay the implementation of the NMP.
Australia’s national medicines policy process: balancing
health and economic objectives
Australia, as a participant at the 39th World Health
Assembly in 1986, contributed to the development of
the strategy calling on governments to implement a
NMP. In 1991, the Australian Government established
the Australian Pharmaceutical Advisory Council (APAC)
and the Pharmaceutical Health And Rational use of
Medicines (PHARM) Committee. APAC’s formation
presented an opportunity for all interested parties to
positively contribute on a multi-lateral and consensus
basis to the development of the NMP, while a policy for
the improvement of medicines utilisation was formulated
and adopted in 1992 through the PHARM Committee
and a multisectoral participatory process. In 2000 the first
NMP was formally approved by the government with the
overall goal ‘to meet medication and related health serviceand the former Yugoslav Republic of Macedonia
stralia South-Africa former Yugoslav Republic of Macedonia
99 1996 2001
gh Upper-middle Upper-middle






ional Income (GNI) per capita.
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nomic objectives are achieved’ [22,23]. To reach this goal,
the policy framework addresses the inherent tensions
within the objectives of attaining affordable access to med-
icines, while maintaining a viable pharmaceutical industry,
and achieving quality medicines and health systems.
South Africa’s national medicines policy process: focusing
on equity and access
The focus of South Africa’s first single NMP was on
equity. Under apartheid, the health care system was gener-
ous and highly effective, but only for the white population.
Two separate draft national medicines policy documents
were circulating. The key challenge for the new ANC-led
government was to develop the ANC draft policy into a
truly national policy, and WHO was invited to participate
from the start. After one year the Minister of Health
insisted that the process be completed and one policy
document be prepared based on the three existing drafts
(2 old drafts and a new document discussed with all stake-
holders). This high-level political support resulted in the
final policy document in 1996 [24]. This support also en-
sured that most of the national components of the policy
were successfully implemented in the years that followed,
although the new progressive medicine law was challenged
in court by pharmaceutical industry and delayed for three
years.
Former Yugoslav republic of Macedonia’s national
medicines policy process: joint effort with
WHO involvement
Broad support from WHO in the FYR Macedonia, which
was seriously destabilized by the Kosovo War in 1999 that
led to an exodus of ethnic Albanians into Macedonia, cre-
ated an opportunity to begin the NMP formulation. Prior
to the enactment of the Health Care Law in 1991 and the
establishment of the Ministry of Health, the system of
health care was fragmented with little central governance
or strategic overview although it offered universal accessi-
bility [25,26]. In February 2000, the Ministry of Health
and the WHO Humanitarian Assistance Office in Skopje
organized an initial meeting to discuss the implementation
of a NMP and to present the main aspects of a NMP. In
May 2001, several drafts were combined to produce one
comprehensive document which was officially endorsed
by the FYR Macedonian government in October 2001.
Discussion
The number of NMPs around the world has increased
over the past 25 years with an early increase in low-
income countries and a more recent increase in high-
income countries. Nevertheless, to date, not all countries
have a NMP. If there is no political pressure by national
experts or non-governmental organizations the need toestablish a single comprehensive document may be ab-
sent. Low-income and lower middle-income countries
may be more likely to have a NMP, because access to
medicines is a challenging problem for politicians. In
addition, WHO has focused on low- and middle-income
countries since the 1980s. In high-income countries
access is generally assured, but complex issues related to
rational use, medicines prices, reimbursement and in-
dustry concerns confront policy makers. Although most
wealthier high-income countries have managed without a
comprehensive NMP, they sometimes encounter problems
due to a lack of a single NMP [17]. In most high-income
countries components of a medicines policy are often in
place, but are rarely addressed in a single comprehensive
national medicines policy. In the USA, for example,
matters tend to be managed separately by the Food and
Drug Administration (FDA; regulation), the Federal Trade
Commission (FTC; trading and competition issues), the
National Institutes of Health (NIH; research) and by indi-
vidual states (dispensing). Moreover, states and profes-
sional associations develop and implement many different
aspects of a medicines policy.
The policy development processes of the four case
studies show that the development of a NMP is a com-
plex process that is country specific. Lessons learnt from
the four described policy processes demonstrate that an
appropriate political window is needed for the policy to
be passed; for South Africa and the FYR Macedonia, a
major political event acted as a trigger for initiating the
policy development. Furthermore, all stakeholders must
be involved at an early stage to offer a stable system that
guarantees access, and rational use of medicines. During
the policy development process, countries are forced to
develop a transparent framework so that stakeholders
understand their roles and responsibilities. Countries are
also forced define national priorities based on a balance
between meeting patients’ needs as well as ensuring
effective use of the countries’ resources and other incen-
tives (e.g., maintaining a viable national industry as seen
in the Australian case study).
Policy-making, however, does not stop with the official
adoption of a policy but should create mechanisms for
implementation and monitoring. Large differences exist
between NMPs in how the implementation is managed
and funded. Unless there is a performance-related
budget linked to the policy, adequate implementation
(and monitoring) is unlikely to occur. The policy process
of Sri Lanka clearly showed the struggle to implement
the policy due to generics use guidelines, which the local
industry opposed. A clear policy should be reassessed
from time to time and revised as appropriate - ideally
every 4–5 years. Sufficient staff with appropriate technical
and professional capabilities is required [27]. Indicators or
performance standards are a tool to determine whether
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fects of changes in medicines policy objectives. Inde-
pendent consultants or external professionals may be
invited to complement a national evaluation team. Re-
sources needed for these revisions should be allocated
from the start of the development process. NMPs may
address the importance of monitoring and evaluation,
but indicators for monitoring or an actual monitoring
framework are often lacking within the policy. For the
selected countries, the NMPs of the FYR Macedonia
and Australia provide indicators for monitoring. None
of the policies included independent external evaluation
of the implementation of the NMP.
Even if a NMP indeed exists in a Ministerial Declar-
ation or even in the law, and an implementation plan ex-
ists as well, this does not always mean that the policy
works effectively. Shortcomings in regulatory perform-
ance, lack of access to essential medicines and irrational
use may exist despite the existence of a comprehensive
policy document. An example of this shortcoming was
seen in the failure to protect Australia (and other coun-
tries) from the COX-2 inhibitor regulatory failure [28].
Thus, a more complex NMP with major divisions of re-
sponsibilities between the central and state governments
must include both the easily agreed-upon common in-
terests but must also resolve the conflict areas in order
to reach an agreed, national compromise involving all
parties.
Although most pharmaceutical problems are best
addressed at the national level through the use of NMPs,
there could be cases where medicines policy issues are
better managed at a regional or global level because
some problems extend beyond the boundaries of na-
tional borders. There are many regional organizations
working together to harmonise the regulatory aspects
of NMPs, e.g. the European Medicines Agency (EMA)
centralised registration process, and the implementation
of various aspects of the NMP. Regional groupings such
as ASEAN and COMESA are collaborating to harmonise
regulation and pricing information and coordinate NMPs
across countries within their regions.Conclusion
Experiences in many countries have shown that pharma-
ceutical problems can best be addressed in a compre-
hensive policy, as piecemeal approaches can leave
important problems unsolved. Case studies in four coun-
tries showed that the policy process is just as important
as the policy document since the process must create a
mechanism by which all stakeholders are brought to-
gether and a sense of collective ownership of the final
policy may be achieved. This may be crucial in view of
the challenges to implement and monitor the NMP.Appendix
Full description of NMP development policy processes
Sri Lanka’s national medicines policy process: promoting
generics despite opposition
In 1959, Sri Lanka had a limited list of essential medicines
and the use of generics was compulsory in public health
care. Professor Senaka Bibile, a Sri Lankan pharmacolo-
gist, played a leading role in developing a rational pharma-
ceutical policy which ensured that the poor people would
get good quality medicines at the lowest possible price to
the country and that doctors would prescribe the mini-
mum required medicines to treat the patient's illness. The
country’s limited list of medicines was extended to the
private sector in 1972, when the state became the sole im-
porter of all pharmaceuticals through its trading arm, the
State Pharmaceuticals Corporation (set up by professor
Senaka Bibile), which also supplied the private market. By
setting up the State Pharmaceutical Corporation and call-
ing for worldwide bulk tenders the stranglehold of multi-
nationals on the medicines trade was broken. This made
them compete with each other and with generic medicines
producers which enabled poor countries to obtain medi-
cines much cheaper. This policy was supported by WHO
and other UN agencies with enormous benefit to develop-
ing countries. [28] The government’s attempt to extend
control to the private sector provoked controversy within
the health services and the private sector, and particu-
larly within the pharmaceutical industry. Cooperation
with international organisations and non-governmental
organisations was necessary to develop and implement
a medicine policy that addressed the country’s growing
dependence on a number of multinational companies
that monopolised the global trade in medicines [29]. In
1977, a new government came into power with neo-
liberal policies. The limited list of medicines was applied
only to the public sector and the use of brand names
and aggressive promotion of brands in the private sector
returned. In 1991 an attempt was made to develop a
NMP, but the attempt failed as did a subsequent attempt
in 1996. These efforts were not confined to the NMP
alone; both in 1991 and 1996 a health task force was set
up to recommend ways and means of restructuring the
entire health service system. The documents they pro-
duced were accepted by the Ministry of Health, but
were not endorsed by the government. Two important
factors for this failure were the absence of participation
of civil society in the two task forces and the lack of
health reform campaigns by civil society organizations.
In 2006 Sri Lanka succeeded in developing a NMP. In
that year, the process was quite different from the previ-
ous attempts. Health Action International Asia – Pacific
(HAIAP) and its network partner ‘The Peoples Movement
for Rights of Patients’ (PMRP) began campaigning and
lobbying for the formulation of a NMP and convened a
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the need for a NMP. In 2005, two workshops facilitated by
WHO/SEARO were held for all stakeholders, including
representatives from the Ministry of Health, academia,
health professionals and associations, trade unions, the
private pharmaceutical industry and trade, and civil soci-
ety. HAIAP and PMRP took an active role and the NMP
was accepted by consensus, forwarded to the Ministry of
Health, approved by the cabinet, and passed by the Parlia-
ment in 2006.
The objectives of the current 2006 NMP for Sri Lanka
for both public and private sectors are:
1) to ensure the availability and affordability of
effective, safe and quality medicines relevant to
health care needs of the people in a sustainable and
equitable manner;
2) to promote the rational use of medicines by
healthcare professionals and consumers;
3) to promote local manufacture of essential
medicines [28].
In the three years since the endorsement of the policy
by the government, the Ministry of Health appointed a
National Standing Committee (NSC) with 18 members
representing all stakeholders and a mandate to implement
the NMP. The NSC appointed a subcommittee to prepare
a draft ‘Act to Regulate Medicinal Drugs and Devices,
Cosmetics, Neutracentical and Functional Foods’. The
draft was presented to the Ministry of Health in early
2008; however, little has happened to the data of data col-
lection (2009). There was strong lobbying by the private
pharmaceutical industry and trade against the NMP even
though they had participated as a stakeholder. Generic
promotion and substitution are two components in the
NMP that the industry vehemently opposed and they have
successfully lobbied to delay the implementation of the
NMP. The PMRP has filed a fundamental rights petition
in the supreme court of Sri Lanka asking the court to dir-
ect the Ministry of Health to implement the NMP. PMRP
argues that any delay in the implementation causes a de-
nial of the fundamental right of the people to access life
saving medicines at affordable prices (Balasubramaniam
K. Personal communication).
Australia’s national medicines policy process: balancing
health and economic objectives
Australia, as a participant at the 39th World Health
Assembly in 1986, contributed to the development of the
strategy calling on governments to implement a NMP.
The need for a comprehensive NMP was further illus-
trated in the ‘Health for All Australians’ document issued
jointly by all State and Federal Australian Health Ministers
in 1988. It was recognised that there was considerablemedicine-related morbidity and mortality in Australia,
much of which was preventable. There were, however,
very few strategies or (inclusive) structures in place to
support improvements in medication use. Furthermore,
the research efforts and knowledge of successful strategies
to improve medication use were also limited, both within
Australia and internationally. In 1989, the Consumers
Health Forum widely circulated a document ‘Towards a
National Drug Policy’ which crystallised the concept of an
integrated medicine policy (combining several current
existing ad-hoc policy measures) and the need for action
on how medicines are used. In 1991, the Australian
Government established the Australian Pharmaceutical
Advisory Council (APAC) and the Pharmaceutical Health
And Rational use of Medicines (PHARM) Committee.
Following the successful establishment of PHARM and
APAC, the government had begun to consider the articu-
lation of a National Medical Drug Policy. A policy for the
improvement of medicines utilisation was formulated and
adopted in 1992 through the PHARM Committee and a
multisectoral participatory process.
Eight years later, in 2000, the first NMP was formally ap-
proved by the Australian government [22,23]. Under the
auspices of the APAC, the policy integrated pre-existing
elements within the new Quality Use of Medicines policy.
The NMP was formulated in a partnership of government,
healthcare professional organisations, the pharmaceutical
industry, distributors, healthcare consumers and other
stakeholders. APAC’s formation in 1991 presented an op-
portunity for all interested parties to positively contribute
on a multi-lateral and consensus basis to the development
of the NMP. Australia is one of the few developed coun-
tries with a comprehensive NMP and the most recent ex-
ample of a high-income country establishing a NMP. The
Australian policy’s four major objectives are to ensure:
1) timely access to the medicines that Australians need,
at a cost individuals and the community can afford,
through the Therapeutic Goods Administration and
through the Pharmaceutical and Repatriation Benefits
Schemes;
2) that medicines meet appropriate standards of
quality, safety and efficacy;
3) maintaining a responsible and viable national
pharmaceutical industry, through the industry
portfolio;
4) quality use of medicines [23].
The overall policy goal of Australia’s NMP is ‘to meet
medication and related health service needs, so that both
optimal health outcomes and economic objectives are
achieved’. To reach this goal, the policy framework ad-
dresses inherent tensions within the objectives of attaining
affordable access to medicines while maintaining a viable
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and health systems.
Political pressure by national experts and non-govern-
mental organizations had a major influence on the
development of Australia’s NMP [11,30-32]. While much
has been achieved in a decade, the development and
marketing of new medicines, the use of new technolo-
gies and sources of medicines information, the costs of
medicines, and perhaps most importantly, the increased
interest consumers have taken in their health care,
present further issues for policy development and imple-
mentation [33].
NMPs often do not address problems in other coun-
tries or what has been experienced when safety issues
were at stake. Although this is a matter that concerns
many countries, Vitry and colleagues showed that policy
stakeholders failed to protect Australia from the COX-2
(cyclo-oxygenase-2) inhibitor regulatory failure, despite
the fact that Australia’s NMP aims to ensure quality use
of medicines. They found that regulators did not appro-
priately warn prescribers about potential cardiovascular
risks. The Pharmaceutical Benefits Scheme (PBS) did
not limit unjustified expenditures on COX-2 inhibitors
and pharmaceutical companies ran intense and mislead-
ing promotional campaigns on COX-2 inhibitors without
adequate controls. Independent medicines information
was insufficient to counter the effects of the millions of
dollars spent on advertising in Australia. Their conclu-
sion was that the core elements of the NMP, in particu-
lar the medicine approval process, the post-marketing
surveillance system, the control of medicine promotion,
and the quality of independent medicine information, re-
quired major reappraisal to avoid similar disasters in the
future [34]. Fundamental to this is the development and
utilization of performance indicators to provide a set of
objective criteria by which the implementation and effect
of strategies for quality use of medicines can be moni-
tored [35,36].
South Africa’s national medicines policy process: focusing
on equity and access
In 1993, prior to the first democratic elections after
apartheid, two separate draft national medicines policy
documents were circulating. One was written by the
government at the time, with input from academies at
the University of Cape Town (a famous ‘white’ university),
and another by the African National Congress (ANC).
After a democratically elected ANC-led government was
established in April 1994 under President Mandela, a
national pharmaceutical policy committee was appointed
by the Minister of Health with the following objectives:
1) develop a pricing plan for medicines to be used in
South Africa in the public and private sectors;2) develop a plan to ensure that medicines are tested
and evaluated for effectiveness in the South
African context of treatment using epidemiological
approaches;
3) develop an Essential Medicines List to be used in
the public sector and prepare treatment guidelines
for health personnel;
4) develop specific strategies to increase the use of
generic medicines in South Africa;
5) prepare a plan for effective procurement and
distribution of medicines in South Africa, particularly
in the rural areas;
6) investigate traditional medicines; and
7) rationalize the structure for pharmaceutical
services [24].
The key challenge for the new government was to
develop the ANC draft policy into a truly national pol-
icy, and WHO was invited to participate from the start.
In November 1994, the committee presented a first re-
port of its findings to the Minister of Health, and a new
discussion document was disseminated based on the rec-
ommendations. This draft was used as the basis for wide
consultations and discussions with health care providers,
academia, other ministries, provincial and district repre-
sentatives, professional organizations, pharmaceutical
industry and patients. The process took time and after
one year the Minister of Health insisted that the process
be completed and one policy document be prepared
based on the three existing drafts. This high-level political
support resulted in the final policy document which was
adapted by the Cabinet and published in 1996 [24].
The focus of the new policy was on equity. Under
apartheid, the health care system was generous and
highly effective, but only for the white population. Less
than one quarter of the national health care budget was
left for the remaining three quarters of the population
along legally defined racial categories. The real challenge
was to reduce overconsumption in the sophisticated
parts of the system, e.g. the teaching hospitals, without
losing their good quality and reputation, and make these
facilities available for everyone. Another challenge was
to use the savings to strengthen the rural services, which
were the main source of care for the majority of the
population. In all segments of the system, overuse and
waste of medicines had to be reduced. Key tools, in this
respect, were the development of national treatment
guidelines and lists of essential medicines for all levels of
health care. WHO contributed to the policy process by
breaking the technical isolation that international sanc-
tions had caused, and by supplying the government with
information on practical experiences from successful
countries, such as Zimbabwe and Australia. WHO also
acted as an ‘honest broker’ to support the government
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helped develop and implement a five-year technical
support programme - the South Africa Drug Action
Programme (SADAP) [37].
The policy was largely successful, especially due to the
political window of opportunity after the 1994 election
and the high-level political support. Most of the national
components of the policy (treatment guidelines, national
medicine list, review of the national regulatory agency)
were successfully implemented in the years that followed.
However, the new medicine law, which included several
progressive, but controversial, pricing policy components,
such as generic substitution and parallel importation, was
challenged in court by the research-based local and inter-
national pharmaceutical industry and delayed for three
years. For various political reasons, some of the provinces
remained skeptical and hesitated to become partners in
the process. Yet, overall the policy was effective in making
the government and the various stakeholders aware of the
need for change, and in paving the way for the develop-
ment of the pharmaceutical sector in the decade to follow.
Several senior government officials, now in high office,
were involved in SADAP in their formative years. The
policy document of 1996 remains a strong text which can
serve as an example for other countries [10,38].
Former Yugoslav Republic of Macedonia’s national
medicines policy process: joint effort with WHO involvement
The Former Yugoslav Republic (FYR) of Macedonia
became independent in 1991 following the break-up of
Yugoslavia and remained at peace during the Yugoslav
wars of the early 1990s. However, the country was ser-
iously destabilized by the Kosovo War in 1999. Following
the exodus of ethnic Albanians from Kosovo into
Macedonia and Albania at the end of the Balkan civil con-
flict, broad support from WHO in the FYR Macedonia
also created an opportunity to begin NMP formulation.
Prior to the enactment of the Health Care Law in 1991
and the establishment of the Ministry of Health, the
system of health care was fragmented with little central
governance or strategic overview, although it offered uni-
versal accessibility [25,26]. In February 2000, the Ministry
of Health and the WHO Humanitarian Assistance Office
in Skopje organized an initial meeting to discuss the im-
plementation of a NMP and to present the main aspects
of a NMP. In April 2000, a group of 14 experts were
appointed by the Minister of Health to work on the devel-
opment and formulation of the NMP strategy document.
Five working groups were created to develop specific ele-
ments of the policy: legislation and regulations, medicine
selection, medicine information, rational medicine use,
supply and economic strategies, and human resource
development. Several meetings which were facilitated by
international consultants were held before the NMPadoption workshop. In May 2001, several drafts were
combined to produce one comprehensive document
which was officially endorsed by the FYR Macedonian
government in October 2001. While the Ministry and the
Health Insurance Fund have continued to further develop
and implement the medicines policy, a national working
group completed an analysis of the pharmaceutical sector
under the umbrella of the WHO Good Governance for
Medicines Project [39]. In collaboration with the Ministry
of Health, the policy implementation will be supported in
the future. The country’s NMP includes a list of indicators
for monitoring NMP implementation [40,41].
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